Matthew Alexander Sleeman

This inventor holds 12 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Medimmune Limited, Zenyth Operations Pty. Ltd., Elan Pharma International Limited. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Alexander Sleeman. Retrieved from https://idiyas.com/inventor/matthew-alexander-sleeman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 7)

% Patents Active = 91.7

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Cambridge, GB (2012 - 2023)
Cambridgeshire, GB (2018 - 2024)

Company Filing History:

Zenyth Operations Pty. Ltd.

patents

1 out of 80

Elan Pharma International Limited

patents

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11897949 - Compounds and methods for treating pain (2024-02-13),

2. 11738081 - Polynucleotides encoding IL33 antibodies and methods of using the same (2023-08-29),

3. 11053307 - Compounds and methods for treating pain (2021-07-06),

4. 10668150 - IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same (2020-06-02),

5. 10457728 - Compounds and methods for treating pain (2019-10-29),

6. 9884911 - Compounds and methods for treating pain (2018-02-06),

7. 9701746 - Methods of treating neuropathic pain with specific binding members for NGF (2017-07-11),

8. 9315571 - Specific binding members for NGF (2016-04-19),

9. 9085628 - Antibody molecule for human GM-CSF receptor alpha (2015-07-21),

10. 8865166 - Antibodies to IL-17A and uses thereof (2014-10-21),

11. 8506960 - Antibody molecule for human GM-CSF receptor alpha (2013-08-13),

12. 8263075 - Antibody molecule for human GM-CSF receptor alpha (2012-09-11),

Title: The Innovative Contributions of Matthew Alexander Sleeman

Introduction

Matthew Alexander Sleeman is a prominent inventor based in Cambridgeshire, GB. He has made significant contributions to the field of pain management and immune disorders through his innovative patents. With a total of 12 patents to his name, Sleeman's work has the potential to impact many lives positively.

Latest Patents

One of Sleeman's latest patents focuses on "Compounds and methods for treating pain." This disclosure provides compositions and methods for controlling pain, particularly through the co-administration of an NGF antagonist and a TNFα antagonist. The method offers improved pain control, demonstrating that the combination of these antagonists can be more effective than administering them separately. Another notable patent involves "Polynucleotides encoding IL33 antibodies and methods of using the same." This invention provides isolated IL-33 proteins and antibodies that can modulate cytokine activity, which is crucial for treating immune and inflammatory disorders.

Career Highlights

Throughout his career, Sleeman has worked with reputable companies such as Medimmune Limited and Zenyth Operations Pty. Ltd. His experience in these organizations has contributed to his expertise in developing innovative solutions for complex medical challenges.

Collaborations

Sleeman has collaborated with notable professionals in his field, including David C Lowe and Emma Suzanne Cohen. These collaborations have likely enriched his research and development efforts, leading to groundbreaking inventions.

Conclusion

Matthew Alexander Sleeman's contributions to the field of pain management and immune disorders through his patents highlight his innovative spirit and dedication to improving healthcare. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.